155 related articles for article (PubMed ID: 26073569)
21. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
22. Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort.
Kanamori T; Sanada M; Ri M; Ueno H; Nishijima D; Yasuda T; Tachita T; Narita T; Kusumoto S; Inagaki A; Ishihara R; Murakami Y; Kobayashi N; Shiozawa Y; Yoshida K; Nakagawa MM; Nannya Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Horibe K; Handa H; Ogawa S; Iida S
Br J Haematol; 2020 Dec; 191(5):755-763. PubMed ID: 32386081
[TBL] [Abstract][Full Text] [Related]
23. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
[TBL] [Abstract][Full Text] [Related]
24. Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion.
Yoshihara K; Yoshihara S; Matsuda I; Imado T; Matsuo S; Okada M; Shimizu Y; Hirota S; Fujimori Y
Ann Hematol; 2020 Jun; 99(6):1405-1407. PubMed ID: 32125468
[No Abstract] [Full Text] [Related]
25. Evolving role of stem cell transplantation in multiple myeloma.
Harousseau JL; Moreau P
Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
[TBL] [Abstract][Full Text] [Related]
27. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Mian M; Tinelli M; DE March E; Turri G; Meneghini V; Pescosta N; Berno T; Marabese A; Mondello P; Patriarca F; Pizzolo G; Semenzato G; Cortelazzo S; Zambello R
Anticancer Res; 2016 Mar; 36(3):1059-65. PubMed ID: 26976998
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
Chin M; Sive JI; Allen C; Roddie C; Chavda SJ; Smith D; Blombery P; Jones K; Ryland GL; Popat R; Rismani A; D'Sa S; Rabin N; Gale RE; Yong KL
Blood Cancer J; 2017 Sep; 7(9):e610. PubMed ID: 29016571
[No Abstract] [Full Text] [Related]
30. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Rajkumar SV
Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663
[TBL] [Abstract][Full Text] [Related]
31. United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.
Rabin N; Lai M; Pratt G; Morgan G; Snowden J; Bird J; Cook G; Bowcock S; Owen R; Yong K; Wechalaker A; Low E; Davies F;
Int J Lab Hematol; 2014 Dec; 36(6):665-75. PubMed ID: 24673823
[TBL] [Abstract][Full Text] [Related]
32. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
[TBL] [Abstract][Full Text] [Related]
33. The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
Joks M; Jurczyszyn A; Machaczka M; Skotnicki AB; Komarnicki M
Eur J Haematol; 2015 Feb; 94(2):109-14. PubMed ID: 25039659
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
Hematology; 2007 Jun; 12(3):235-9. PubMed ID: 17558699
[TBL] [Abstract][Full Text] [Related]
36. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
[TBL] [Abstract][Full Text] [Related]
37. Emerging trends in the clinical use of bortezomib in multiple myeloma.
Richardson PG; Schlossman R; Mitsiades C; Hideshima T; Munshi N; Anderson K
Clin Lymphoma Myeloma; 2005 Sep; 6(2):84-8. PubMed ID: 16231845
[TBL] [Abstract][Full Text] [Related]
38. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
[TBL] [Abstract][Full Text] [Related]
39. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
Klein U; Jauch A; Hielscher T; Hillengass J; Raab MS; Seckinger A; Hose D; Ho AD; Goldschmidt H; Neben K
Cancer; 2011 May; 117(10):2136-44. PubMed ID: 21523726
[TBL] [Abstract][Full Text] [Related]
40. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
